Indian Immunologicals And ICMR Sign MoU For Zika Vaccine

Hyderabad: Vaccine maker Indian Immunologicals (IIL) and Indian Council of Medical Research (ICMR) have signed a memorandum of agreement (MoA) for clinical development of the country’s first codon de-optimised live attenuated Zika vaccine.

ICMR will be funding phase I clinical trial costs, including those relating to the conduct, investigations and monitoring of clinical trials under the agreement. The trial will be conducted at the ICMR network sites in India, IIL said in a release on Thursday.

ICMR’s phase I trial network, launched last year, facilitates first-in-human safety studies for innovative and affordable frontier medtech, including small molecules, biologics and vaccines. With four phase-I sites — ACTREC-Mumbai, KEM Hospital-Mumbai, SRM-Chennai and PGIMER-Chandigarh — fully operational, Indian innovators no longer need to go abroad for phase-I trials, D-G of ICMR Rajiv Bahl said.

IIL has partnered with Griffith University, Australia, to develop the codon de-optimised live attenuated Zika vaccine, which has completed extensive pre-clinical evaluations and received permission from Indian regulatory authority to produce GMP grade materials for clinical developmental work.

The company is working on developing vaccines for several neglected emerging diseases. The list includes Zika, Kyasanur Forest Disease (KFD), Chikungunya and a SARS-CoV-2 intranasal booster vaccine, IIL deputy MD Priyabrata Pattnaik said.

A viral infection, Zika is mostly a mosquito-borne disease. Currently there is no vaccine available against Zika, IIL said.

Related Posts

  • Pharma
  • February 10, 2025
  • 89 views
DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

Mumbai:  The Directorate General of Foreign Trade (DGFT), under the ministry of commerce & industry, has announced amendments to the Standard Input Output Norms (SION) for the export of erythromycin…

  • Pharma
  • February 10, 2025
  • 96 views
CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

THIRUVANANTHAPURAM: CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) in Thiruvananthapuram has developed a technology that converts pathogenic biomedical waste into value-added soil additives that eliminate the need for costly…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

An Index To Gauge States For Drug Enforcement, Improve Drug Quality

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

DGFT Amends Standard Input Output Norms For Erythromycin Stearate Tablets

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

As Always Ahead of Game in healthcare, Doc was first to vote too

As Always Ahead of Game in healthcare, Doc was first to vote too

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister